Premier Alternatives

Treeline Biosciences

Watertown, MA · Founded 2021 · Privately Held (backing)

Developer of transformative precision medicines intended to treat cancer and other serious conditions. Treeline Biosciences is based in Watertown, MA and was founded in 2021. It is valued at about $1.3 billion as of Oct 2026, set by institutional fund marks. It has raised $1.1 billion across 2 recorded rounds; the latest was a $200 million later-stage round in Aug 2025.

PMV mark · valuation
$1.3B
Oct 2026
Priced at
—
Total raised
$1.1B
Last round
Later Stage VC
Aug 2025

Treeline Biosciences key facts

as of Oct 2026
  • Developer of transformative precision medicines intended to treat cancer and other serious conditions.
  • Treeline Biosciences is valued at approximately $1.3B as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $1.1B across 2 recorded rounds; the latest was Later Stage VC ($200.1M) in Aug 2025.
  • Notable investors include GV, OrbiMed, ARCH Venture Partners, T. Rowe Price Group, Fidelity — 14 tracked in total.
  • 2 institutional filers report fund marks on Treeline Biosciences across 18 filings.
  • Treeline Biosciences has filed 2 Form Ds with the SEC since 2024, most recently Sep 2025 ($200.1M sold to 22 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$1.3B

Reported valuation; nothing comparable since.

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Treeline Biosciences with a free account
  • ·The complete investor list: 14 names
  • ·Watch Treeline Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Treeline Biosciences

2 filers · latest Jul 2026

2 SEC-registered funds reported 18 fair-value marks on Treeline Biosciences between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 18 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Treeline Biosciences funding rounds

2 rounds
Aug 2025Later Stage VC$200.1MSEC filing▮
Oct 2024Later Stage VC$421.8MSEC filing▮
Full funding history →

Treeline Biosciences valuation

Treeline Biosciences is valued at approximately $1.3 billion as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Treeline Biosciences's record added 3 institutional fund marks (latest period Jul 2026).

How much has Treeline Biosciences raised?

Treeline Biosciences has raised $1.1 billion in total; 2 of its rounds are on record. The largest on record was a $422 million later-stage round in Oct 2024; the most recent was a $200 million later-stage round in Aug 2025.

Treeline Biosciences has filed 2 Form Ds with the SEC since 2024, most recently in Sep 2025 ($200 million sold to 22 investors).

Institutional holders and vehicles

2 SEC-registered funds reported 18 fair-value marks on Treeline Biosciences between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Treeline Biosciences investors

14 investors are on record for Treeline Biosciences, including GV, OrbiMed, ARCH Venture Partners and T. Rowe Price Group. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 growth equity firm. The later-stage round in Aug 2025 drew 22 investors.

About Treeline Biosciences

Developer of transformative precision medicines intended to treat cancer and other serious conditions. The company's platform is involved in assessments of normal and disease pathophysiology, experimental results, genomics, and pattern recognition to develop transformative precision addressing unmet patient needs, enabling medical professionals to cure cancer and other serious conditions.

Sector
Healthcare
HQ
Watertown, MA, United States
Founded
2021
Employees
149
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.